Instacart stock rises as company expands Costco partnership to Europe

Investing.com -- Wolfe Research raised its price target on Nvidia to $275 from $250 saying rack-scale systems, higher average selling prices and sustained margins will drive earnings well beyond current expectations.

Nvidia recognizes revenue when it sells completed boards to cloud service providers, after manufacturing and packaging at TSM and board assembly at Foxconn.

Those boards account for about 75% of the final rack price, according to Wolfe’s supply chain checks.

Reported prices are about $3 million for GB200 NVL72 racks and $4.3 million for GB300 NVL72, with next-generation Rubin racks seen at $5 million to $6 million.

Wolfe estimates Blackwell rack shipments reached about 1000 units per week by the end of calendar 2025 and will hold that pace through 2026, implying 50000 to 60000 racks for the year.

It expects Rubin to ramp in the second half of 2026 without delays, helped by design changes that simplify assembly, and models a similar 1000-per-week run rate.

Wolfe forecasts about 55000 Blackwell racks and 20000 Rubin racks in 2026, rising to 55000 Rubin racks and 15000 Rubin Ultra racks in 2027. It expects Nvidia to continue shifting its mix toward rack-scale systems, with slower growth in HGX and other standalone platforms.

Those volumes translate into about 7.2 million data center GPU units in 2026, up 35% year on year, and 9 million units in 2027, up 25%. Wolfe models data center revenue exceeding $450 billion in 2027, driven by unit growth and roughly 20% higher ASPs as Nvidia moves from Blackwell to Rubin.

For Rubin Ultra, Wolfe assumes rack pricing of about $10 million, reflecting a doubling of GPUs per rack. It said this is conservative, noting that higher pricing could add $10 billion to $12 billion in revenue for every additional $1 million per rack above its estimates.

Wolfe expects Nvidia to sustain pricing power and gross margins around 75%, citing continued generation-on-generation performance gains and limited competitive pressure at the high end.

It sees 2027 estimates of $457 billion in data center revenue and $11.50 in EPS, with a bull case of $500 billion and $12. The new target values the stock at about 23 times bull-case earnings.

Investing.com -- Jiuzi Holdings Inc (NASDAQ:JZXN) stock fell 11.8% in premarket trading Friday after the company announced it has secured a $30 million investment from Xinhui Solar Technology Group Co., Ltd.

The investment will support a partnership focused on developing electric vehicle charging infrastructure and new energy vehicle service networks across Southeast Asia. The companies plan to establish charging networks covering major cities and key transportation corridors in the region through a phased investment approach.

Under the agreement, Xinhui Solar will provide both equity investment and participate in co-development initiatives with Jiuzi. The partnership aims to leverage Xinhui’s local resources, channels, and operating experience in Southeast Asia to accelerate Jiuzi’s overseas expansion.

Jiuzi Holdings expects to achieve synergies across "capital + technology + channels" through this collaboration, which could strengthen its brand influence in Southeast Asia’s new energy mobility sector.

Xinhui Solar expressed optimism about Southeast Asia’s growth potential in electric vehicle adoption and charging infrastructure development, citing Jiuzi’s capabilities in charging technology, network operations, and service systems as key factors in the partnership.

The companies plan to progressively build out charging and service networks to enhance regional service capacity and operational efficiency in response to the growing EV penetration and charging demand across Southeast Asia.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Nuwellis Inc (NASDAQ:NUWE) stock dropped 17% in premarket trading Friday after the medical technology company announced the appointment of a new Chief Financial Officer.

The cardiorenal care-focused company named Carisa Schultz as its new CFO, effective February 2, 2026. Schultz most recently served as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange.

Nuwellis CEO John Erb highlighted Schultz’s public company experience and healthcare background in the announcement. "Her expertise and disciplined approach will be instrumental as we continue to execute our strategy and advance our cardiorenal platform," Erb stated.

Schultz brings experience from various financial leadership roles, including positions at Boston Scientific, along with Big Four public accounting experience. At NeueHealth, she led enterprise finance, treasury, and corporate development activities.

"I’m excited to join Nuwellis at an important juncture in its growth," Schultz said. "The company’s focus on precision cardiorenal care represents a meaningful opportunity, and I look forward to working with the leadership team to support long-term value creation."

Nuwellis develops precision fluid management technologies for patients with fluid overload.

The company also announced Thursday evening that it would be acquiring Rendiatech Ltd., an Israeli medtech company focused on automated kidney function monitoring.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- London’s FTSE 100 edged higher on Friday as markets weighed U.S. President Donald Trump’s pick of Kevin Warsh to lead the Federal Reserve, with European shares advancing and the pound slipping below $1.38.

As of 1403 GMT, the blue-chip index rose 0.3%% and the British GBP/USD fell 0.4% against the dollar to 1.3752.

DAX index in Germany gained 0.8%, the CAC 40 in France rose 0.6%.

UK round up

AstraZeneca PLC (ST:AZN) will pay Chinese drugmaker CSPC Pharmaceutical Group up to $18.5 billion in a licensing deal for experimental obesity and weight-related drugs, CSPC announced Friday.

The agreement includes an upfront payment of $1.2 billion, with potential additional payments of up to $17.3 billion if certain milestones are met. This deal expands on existing collaboration between the companies in areas including artificial intelligence.

In other market news, Airtel Africa Plc (LAGOS:AIRTELAFRI) shares fell approximately 6%, reversing early gains despite reporting strong third-quarter results. The telecommunications company posted a 31.0% increase in EBITDA to $836 million in constant currency terms, with margins expanding to 49.6%, up 278 basis points year-over-year. The results were driven by strong revenue growth in Nigeria and mobile money services.

Meanwhile, Antofagasta PLC (LON:ANTO) shares dropped more than 4.8% following a downgrade by UBS from "buy" to "neutral." UBS cited limited near-term growth momentum after the Chilean copper miner’s shares surged approximately 135% over the past 12 months on a total shareholder return basis in U.S. dollars, outperforming copper prices by roughly 90% and the COPX index by about 40%.

In the financial sector, Schroders PLC (LON:SDR) has held high-level discussions about potential partnerships to boost growth in its private capital business, according to Reuters. The British asset manager reportedly explored deals for Schroders Capital with French investment firm Wendel and London-listed Bridgepoint Group. These previously undisclosed talks, which took place several months ago, have since been paused for reasons that remain unclear.

Regarding monetary policy, Deutsche Bank expects the Bank of England to keep its Bank Rate at 3.75% in its February decision. The German bank forecasts a 7-2 vote split, with external Monetary Policy Committee members Alan Taylor and Swati Dhingra likely to favor a rate cut. Deutsche Bank analysts pointed to signs of economic resilience in the UK despite a fragile labor market, where unemployment has reached 5.1% in the three months to October.

Investing.com -- Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) stock rose 2.5% in premarket trading Friday after the company announced compelling preclinical data for NDL2, its potentially first-in-class protein degrader targeting nuclear PD-L1.

The Sydney-based oncology company revealed that NDL2 is designed to eliminate nuclear PD-L1, which Kazia identified as a previously unrecognized driver of immunotherapy resistance and metastatic progression. According to the company, this intracellular target is not addressed by currently approved PD-1/PD-L1 antibodies.

In preclinical models of triple-negative breast cancer, NDL2 reduced primary tumor volume by 49% as monotherapy and 73% when combined with anti-PD-1 therapy. The combination approach also demonstrated a 50% reduction in lung metastases.

"The pharmaceutical industry is clearly signalling that targeted protein degradation represents a transformational opportunity in oncology," said Dr. John Friend, CEO of Kazia Therapeutics. "What differentiates NDL2 is that we are applying protein degradation to PD-L1 as one of the most clinically validated targets in cancer, while addressing a resistance mechanism not reached by existing therapies."

The data were generated by Professor Sudha Rao and her team at QIMR Berghofer, showing that nuclear PD-L1 promotes aggressive cancer characteristics including epithelial-to-mesenchymal transition, cancer stem-like phenotypes, and immune evasion.

Kazia reported that NDL2 demonstrated a favorable preclinical safety profile with no observed toxicity. The company is advancing IND-enabling studies with plans to initiate first-in-human clinical trials in 2027, subject to regulatory review.

The company plans to present additional data at an oncology-focused scientific meeting in the second quarter of 2026, with further program updates expected in the first quarter of 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.